We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Drug Developers Identify Novel Target for Treatment of Autoimmune Disease

By LabMedica International staff writers
Posted on 05 May 2009
A recent study identified the target molecule for quinoline-3-carboxamides (Q compounds), a class that developers of drugs for treatment of autoimmune and inflammatory diseases have been working with for more than 25 years.

Q compounds have proven effective in clinical trials for the treatment of multiple sclerosis (MS) and type I diabetes. More...
Furthermore, they are currently in phase III clinical development for the treatment of MS and are about to enter phase II for the treatment of systemic lupus erythematosus (SLE). However, despite intensive research efforts, the target molecule and the mode of action of this class of compounds have remained unknown for over 25 years.

Q compounds are unique in that they have a potent effect on disease development in several animal models of autoimmune or inflammatory disease without inducing suppression of adaptive immunity. In the current study, investigators from Lund University (Sweden), the University of Muenster (Germany), and the company Active Biotech AB (Lund, Sweden) successfully identified a molecular target for quinoline compounds.

The investigators reported in the April 28, 2009, online edition of the journal PLoS Biology that the target was a protein called S100A9. This protein belongs to the family of calcium-binding S100 proteins and has been extensively studied. It is expressed in granulocytes and at early stages of monocyte differentiation. S100A9 has also been detected on the cell surface of mouse macrophages at sites of inflammation, but the role of surface-bound S100A9 in immunity and inflammation is still unclear.

In the current study, the investigators revealed that S100A9 interacted with two known proinflammatory receptors (Toll-like receptor 4 [TLR4] and receptor of advanced glycation end products [RAGE]), and that this interaction was inhibited by quinoline compounds.

These findings allowed the authors to conclude that, " S100A9 appears to be a focal molecule in the control of autoimmune disease via its interactions with proinflammatory mediators. The specific binding of quinoline-3-carboxamides to S100A9 explains the immunomodulatory activity of this class of compounds and defines S100A9 as a novel target for treatment of human autoimmune diseases."

Active Biotech AB currently has three experimental quinoline drugs (laquinimod, 57-57, and TASQ) under active investigation.

Related Links:

Lund University
University of Muenster
Active Biotech



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.